In the first seven months of the novel coronavirus pandemic, inpatient therapy choices have been considerably influenced by pre-publications, media attention, clinical trials, emergency use authorizations, and regional drug availability. In this observational study, we examine patterns in inpatient medication use since the start of the pandemic. Use of the leading therapies over time represents the dramatic changes in standard of care for treating hospitalized patients with COVID-19. Dexamethasone and remdesivir are the current dominant therapeutics, and both of these therapies have supportive evidence from randomized clinical trials…